Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Oct;81(3):554–558. doi: 10.1038/sj.bjc.6690730

HPV testing in primary screening of older women

J Cuzick 1, E Beverley 1, L Ho 2, G Terry 2, H Sapper 3, I Mielzynska 4, A Lorincz 4, W-K Chan 5, T Krausz 6, P Soutter 6
PMCID: PMC2362918  PMID: 10507785

Abstract

Certain types of the human papilloma virus (HPV) are well established as the primary cause of cervical cancer. Several studies have shown that HPV testing can improve the detection rate of high-grade cervical intraepithelial neoplasia (CIN), but these have been carried out primarily in younger women. In this study we evaluated the role of HPV testing as an adjunct to cytology in women aged 35 or over. An additional aim was to evaluate commercially available kits for HPV testing. A total of 2988 eligible women aged 34 or more attending for a routine smear in 40 general practitioner practices received HPV testing in addition to routine cytology, after having given written informed consent. Samples were assayed by polymerase chain reaction (PCR) and two versions of the Hybrid Capture test for HPV, and women were invited for colposcopy if there was any cytological abnormality (including borderline smears) or the PCR test was positive. Any apparent abnormality was biopsied and loop-excision was performed as necessary. CIN was judged by histology; 42 women had high-grade CIN, of which six were cytology negative (86% sensitivity for borderline or worse) and three had a borderline smear (79% sensitivity for mild dyskaryosis or worse). The positive predictive value of a borderline smear was only 3.1%. Eleven high-grade lesions were negative by the PCR HPV test (sensitivity 74%). The first generation Hybrid Capture II test had a similar sensitivity but an unacceptably high false positive rate (18.3%), while the newer Hybrid Capture II microtitre kit had a 95% sensitivity and a 2.3% positivity rate in normal women when used at a 2 pg ml−1 cut-off (positive predictive value 27%). Cytology performed very well in this older cohort of women. The newer Hybrid Capture II microtitre test may be a useful adjunct, especially if the results reported here are reproducible in other studies. A combined screening test offers the possibility of greater protection and/or longer screening intervals, which could reduce the overall cost of the screening programme. © 1999 Cancer Research Campaign

Keywords: hybrid capture, cancer screening, cervical cancer, human papillomaviruses

Full Text

The Full Text of this article is available as a PDF (57.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cox J. T., Lorincz A. T., Schiffman M. H., Sherman M. E., Cullen A., Kurman R. J. Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol. 1995 Mar;172(3):946–954. doi: 10.1016/0002-9378(95)90026-8. [DOI] [PubMed] [Google Scholar]
  2. Cuzick J., Szarewski A., Terry G., Ho L., Hanby A., Maddox P., Anderson M., Kocjan G., Steele S. T., Guillebaud J. Human papillomavirus testing in primary cervical screening. Lancet. 1995 Jun 17;345(8964):1533–1536. doi: 10.1016/s0140-6736(95)91086-7. [DOI] [PubMed] [Google Scholar]
  3. Cuzick J., Terry G., Ho L., Hollingworth T., Anderson M. Type-specific human papillomavirus DNA in abnormal smears as a predictor of high-grade cervical intraepithelial neoplasia. Br J Cancer. 1994 Jan;69(1):167–171. doi: 10.1038/bjc.1994.28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Ferenczy A., Franco E., Arseneau J., Wright T. C., Richart R. M. Diagnostic performance of Hybrid Capture human papillomavirus deoxyribonucleic acid assay combined with liquid-based cytologic study. Am J Obstet Gynecol. 1996 Sep;175(3 Pt 1):651–656. doi: 10.1053/ob.1996.v175.a73868. [DOI] [PubMed] [Google Scholar]
  5. Hatch K. D., Schneider A., Abdel-Nour M. W. An evaluation of human papillomavirus testing for intermediate- and high-risk types as triage before colposcopy. Am J Obstet Gynecol. 1995 Apr;172(4 Pt 1):1150–1157. doi: 10.1016/0002-9378(95)91473-0. [DOI] [PubMed] [Google Scholar]
  6. Hildesheim A., Schiffman M. H., Gravitt P. E., Glass A. G., Greer C. E., Zhang T., Scott D. R., Rush B. B., Lawler P., Sherman M. E. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis. 1994 Feb;169(2):235–240. doi: 10.1093/infdis/169.2.235. [DOI] [PubMed] [Google Scholar]
  7. Hirschowitz L., Raffle A. E., Mackenzie E. F., Hughes A. O. Long term follow up of women with borderline cervical smear test results: effects of age and viral infection on progression to high grade dyskaryosis. BMJ. 1992 May 9;304(6836):1209–1212. doi: 10.1136/bmj.304.6836.1209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Ho G. Y., Burk R. D., Klein S., Kadish A. S., Chang C. J., Palan P., Basu J., Tachezy R., Lewis R., Romney S. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst. 1995 Sep 20;87(18):1365–1371. doi: 10.1093/jnci/87.18.1365. [DOI] [PubMed] [Google Scholar]
  9. Huang S., Afonina I., Miller B. A., Beckmann A. M. Human papillomavirus types 52 and 58 are prevalent in cervical cancers from Chinese women. Int J Cancer. 1997 Feb 7;70(4):408–411. doi: 10.1002/(sici)1097-0215(19970207)70:4<408::aid-ijc6>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  10. Jones M. H., Jenkins D., Cuzick J., Wolfendale M. R., Jones J. J., Balogun-Lynch C., Usherwood M. M., Singer A. Mild cervical dyskaryosis: safety of cytological surveillance. Lancet. 1992 Jun 13;339(8807):1440–1443. doi: 10.1016/0140-6736(92)92031-a. [DOI] [PubMed] [Google Scholar]
  11. Kinney W. K., Manos M. M., Hurley L. B., Ransley J. E. Where's the high-grade cervical neoplasia? The importance of minimally abnormal Papanicolaou diagnoses. Obstet Gynecol. 1998 Jun;91(6):973–976. doi: 10.1016/s0029-7844(98)00080-5. [DOI] [PubMed] [Google Scholar]
  12. Londesborough P., Ho L., Terry G., Cuzick J., Wheeler C., Singer A. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int J Cancer. 1996 Oct 21;69(5):364–368. doi: 10.1002/(SICI)1097-0215(19961021)69:5<364::AID-IJC2>3.0.CO;2-3. [DOI] [PubMed] [Google Scholar]
  13. Soutter W. P., Wisdom S., Brough A. K., Monaghan J. M. Should patients with mild atypia in a cervical smear be referred for colposcopy? Br J Obstet Gynaecol. 1986 Jan;93(1):70–74. doi: 10.1111/j.1471-0528.1986.tb07816.x. [DOI] [PubMed] [Google Scholar]
  14. Terry G., Ho L., Szarewski A., Cuzick J. Semiautomated detection of human papillomavirus DNA of high and low oncogenic potential in cervical smears. Clin Chem. 1994 Oct;40(10):1890–1892. [PubMed] [Google Scholar]
  15. Walboomers J. M., de Roda Husman A. M., Snijders P. J., Stel H. V., Risse E. K., Helmerhorst T. J., Voorhorst F. J., Meijer C. J. Human papillomavirus in false negative archival cervical smears: implications for screening for cervical cancer. J Clin Pathol. 1995 Aug;48(8):728–732. doi: 10.1136/jcp.48.8.728. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Walker E. M., Dodgson J., Duncan I. D. Does mild atypia on a cervical smear warrant further investigation? Lancet. 1986 Sep 20;2(8508):672–673. doi: 10.1016/s0140-6736(86)90178-9. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES